JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

Search

Celldex Therapeutics Inc

Cerrado

SectorSalud

26.93 -1.39

Resumen

Variación precio

24h

Actual

Mínimo

26.7

Máximo

27.58

Métricas clave

By Trading Economics

Ingresos

-2.8M

-57M

Ventas

35K

730K

Margen de beneficio

-7,753.425

Empleados

186

EBITDA

-1.1M

-63M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+79.76% upside

Dividendos

By Dow Jones

Próximas Ganancias

4 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

370M

1.8B

Apertura anterior

28.32

Cierre anterior

26.93

Noticias sobre sentimiento de mercado

By Acuity

100%

0%

359 / 373 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Celldex Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

28 oct 2025, 23:50 UTC

Acciones populares

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 oct 2025, 23:25 UTC

Ganancias

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 oct 2025, 23:18 UTC

Ganancias

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 oct 2025, 22:20 UTC

Ganancias

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 oct 2025, 22:13 UTC

Ganancias

Wal-Mart de Mexico Net Profit Falls in 3Q

28 oct 2025, 21:38 UTC

Ganancias

Correction to Visa Sales Jump Article

28 oct 2025, 21:17 UTC

Ganancias

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 oct 2025, 21:07 UTC

Ganancias

Visa Sales Jump as Consumers Keep Spending -- Update

28 oct 2025, 21:02 UTC

Ganancias

Mondelez Tempers Outlook as Costs Rise

28 oct 2025, 23:51 UTC

Charlas de Mercado

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 oct 2025, 23:42 UTC

Charlas de Mercado

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 oct 2025, 23:02 UTC

Ganancias

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 oct 2025, 23:01 UTC

Ganancias

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 oct 2025, 22:46 UTC

Ganancias

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 oct 2025, 22:45 UTC

Ganancias

SK Hynix 3Q Net KRW12.6T >000660.SE

28 oct 2025, 22:44 UTC

Ganancias

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 oct 2025, 22:43 UTC

Ganancias

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 oct 2025, 22:42 UTC

Ganancias

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 oct 2025, 22:40 UTC

Ganancias

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 oct 2025, 22:40 UTC

Ganancias

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 oct 2025, 22:22 UTC

Ganancias

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 oct 2025, 22:22 UTC

Ganancias

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 oct 2025, 22:22 UTC

Ganancias

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 oct 2025, 22:20 UTC

Ganancias

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 oct 2025, 22:02 UTC

Ganancias

Review & Preview: Earnings Extravaganza -- Barrons.com

28 oct 2025, 21:42 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

28 oct 2025, 21:42 UTC

Charlas de Mercado
Ganancias

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 oct 2025, 21:20 UTC

Ganancias

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 oct 2025, 21:19 UTC

Ganancias

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 oct 2025, 21:18 UTC

Ganancias

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Comparación entre iguales

Cambio de precio

Celldex Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

79.76% repunte

Estimación a 12 meses

Media 49.2 USD  79.76%

Máximo 67 USD

Mínimo 25 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Celldex Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

11

Comprar

0

Mantener

1

Vender

Puntuación técnica

By Trading Central

18.91 / 20.63Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat